Restricted accessResearch articleFirst published online 2023-02
Axl and Vascular Endothelial Growth Factor Receptors Exhibit Variations in Membrane Localization and Heterogeneity Across Monolayer and Spheroid High-Grade Serous Ovarian Cancer Models
Vascular endothelial growth factor receptors (VEGFRs) and Axl are receptor tyrosine kinases (RTK) that are targeted in ovarian cancer therapy. Two-dimensional monolayer culture and three-dimensional spheroids are common models for RTK-targeted drug screening: monolayers are simple and economical while spheroids include several genetic and histological tumor features. RTK membrane localization dictates RTK signaling and drug response, however, it is not characterized in these models. We quantify plasma membrane RTK concentrations and show differential RTK abundance and heterogeneity in monolayers versus spheroids. We show VEGFR1 concentrations on the plasma membrane to be 10 times higher in OVCAR8 spheroids than in monolayers; OVCAR8 spheroids are more heterogeneous than monolayers, exhibiting a bimodal distribution of a low-Axl (6200/cell) and a high-Axl subpopulation (25,000/cell). In addition, plasma membrane Axl concentrations differ by 100 times between chemosensitive (OVCAR3) and chemoresistant (OVCAR8) cells and by 10 times between chemoresistant cell lines (OVCAR5 vs. OVCAR8). These systematic findings can guide ovarian cancer model selection for drug screening.
Get full access to this article
View all access options for this article.
References
1.
LisioMA, FuL, GoyenecheA, et al.High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. Int J Mol Sci, 2019; 20(4); doi: 10.3390/ijms20040952
2.
RajaFA, ChopraN, LedermannJA. Optimal first-line treatment in ovarian cancer. Ann Oncol, 2012; 23(SUPPL. 10); doi: 10.1093/annonc/mds315
3.
KatopodisP, ChudasamaD, WanderG, et al.Kinase inhibitors and ovarian cancer. Cancers 2019, Vol 11, Page 1357, 2019; 11(9):1357; doi: 10.3390/CANCERS11091357
4.
ZirlikK, DuysterJ. Anti-angiogenics: Current situation and future perspectives. Oncol Res Treat, 2018; 41(4):166–171; doi: 10.1159/000488087
5.
LedermannJA, EmbletonAC, RajaF, et al.Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet, 2016; 387(10023):1066–1074; doi: 10.1016/S0140-6736(15)01167-8/ATTACHMENT/174BCAFD-C57E-4988-B4B6-331150B40F31/MMC1.PDF
FangY, KaszubaT, ImoukhuedePI. Systems biology will direct vascular-targeted therapy for obesity. Front Physiol, 2020; 11:1–16; doi: 10.3389/fphys.2020.00831
8.
WeddellJC, ImoukhuedePI. Computational Systems Biology for the VEGF Family in Angiogenesis. In: Encyclopedia of Cardiovascular Research and Medicine. Elsevier Inc.; 2018.
9.
FinleySD, ChuL-H, PopelAS. Computational systems biology approaches to anti-angiogenic cancer therapeutics. Drug Discov Today, 2015; 20(2):187–197; doi: 10.1016/J.DRUDIS.2014.09.026
10.
GoelS, DudaDG, XuL, et al.Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev, 2011; 91(3):1071–1121; doi: 10.1152/PHYSREV.00038.2010/ASSET/IMAGES/LARGE/Z9J0031125910015.JPEG
11.
SopoM, AnttilaM, HämäläinenK, et al.Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer. BMC Cancer, 2019; 19(584):1–12; doi: 10.1186/s12885-019-5757-3
12.
SpannuthWA, NickAM, JenningsNB, et al.Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer, 2009; 124(5):1045–1053; doi: 10.1002/ijc.24028
13.
LimJ, YangK, Taylor-HardingB, et al.VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2. Neoplasia (United States), 2014; 16(4):343–353.e2; doi: 10.1016/j.neo.2014.04.003
14.
ZhuC, WeiY, WeiX. AXL receptor tyrosine kinase as a promising anti-cancer approach: Functions, molecular mechanisms and clinical applications. Mol Cancer, 2019; 18(1); doi: 10.1186/s12943-019-1090-3
15.
RankinEB, FuhKC, TaylorTE, et al.AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res, 2010; 70(19):7570–7579; doi: 10.1158/0008-5472.CAN-10-1267
16.
QuinnJM, GreenwadeMM, PalisoulML, et al.Therapeutic inhibition of the receptor tyrosine kinase AXL improves sensitivity to platinum and taxane in ovarian cancer. Mol Cancer Ther, 2019; 18(2):389–398; doi: 10.1158/1535-7163.MCT-18-0537
17.
TianM, ChenX sha, LiL ya, et al.Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis. Acta Pharmacol Sin, 2021; 42(7):1180–1189; doi: 10.1038/s41401-020-00546-8
18.
MullenMM, LomonosovaE, ToboniMD, et al.GAS6/AXL inhibition enhances ovarian cancer sensitivity to chemotherapy and PARP inhibition through increased DNA damage and enhanced replication stress. Mol Cancer Res, 2022; 20(2):265–279; doi: 10.1158/1541-7786.MCR-21-0302/673006/AM/GAS6-AXL-INHIBITION-ENHANCES-OVARIAN-CANCER
19.
GerhardtH, GoldingM, FruttigerM, et al.VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol, 2003; 161(6):1163–1177; doi: 10.1083/jcb.200302047
20.
BlancoR, GerhardtH. VEGF and Notch in tip and stalk cell selection. Cold Spring Harb Perspect Med, 2013; 3(1):1–20; doi: 10.1101/cshperspect.a006569
21.
UemuraA, FruttigerM, D'AmorePA, et al.VEGFR1 signaling in retinal angiogenesis and microinflammation. Prog Retin Eye Res, 2021; 84(February):100954; doi: 10.1016/j.preteyeres.2021.100954
22.
WeddellJC, ImoukhuedePI. Quantitative characterization of cellular membrane-receptor heterogeneity through statistical and computational modeling. PLoS One, 2014; 9(5); doi: 10.1371/journal.pone.0097271
23.
WeickhardtAJ, WilliamsDS, LeeCK, et al.Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. Br J Cancer, 2015; 113(1):37–45; doi: 10.1038/bjc.2015.209
24.
LebokP, HuberJ, BurandtEC, et al.Loss of membranous VEGFR1 expression is associated with an adverse phenotype and shortened survival in breast cancer. Mol Med Rep, 2016; 14(2):1443–1450; doi: 10.3892/mmr.2016.5430
25.
MitraAK, DavisDA, TomarS, et al.In vivo tumor growth of high-grade serous ovarian cancer cell lines. Gynecol Oncol, 2015; 138(2):372–377; doi: 10.1016/j.ygyno.2015.05.040
26.
Al HabyanS, KalosC, SzymborskiJ, et al.Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer. Oncogene, 2018; 37(37):5127–5135; doi: 10.1038/s41388-018-0317-x
27.
LengyelE. Ovarian cancer development and metastasis. Am J Pathol, 2010; 177(3):1053–1064; doi: 10.2353/ajpath.2010.100105
28.
YeeC, DicksonK-A, MuntasirMN, et al.Three-dimensional modelling of ovarian cancer: From cell lines to organoids for discovery and personalized medicine. Front Bioeng Biotechnol, 2022; 10:116; doi: 10.3389/FBIOE.2022.836984/BIBTEX
29.
BrodeurMN, SimeoneK, Leclerc-DeslauniersK, et al.Carboplatin response in preclinical models for ovarian cancer: Comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models. Sci Rep, 2021; 11(1); doi: 10.1038/s41598-021-97434-w
30.
GencogluMF, BarneyLE, HallCL, et al.Comparative study of multicellular tumor spheroid formation methods and implications for drug screening. ACS Biomater Sci Eng, 2018; 4(2):410–420; doi: 10.1021/acsbiomaterials.7b00069
31.
JensenC, TengY. Is it time to start transitioning from 2D to 3D cell culture?. Front Mol Biosci, 2020; 7; doi: 10.3389/fmolb.2020.00033
32.
GunayG, KiritHA, KamatarA, et al.The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration. Gynecol Oncol, 2020; 159(2):563–572; doi: 10.1016/J.YGYNO.2020.09.002
33.
ImoukhuedePI, PopelAS. Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts. Cancer Med, 2014; 3(2):225–244; doi: 10.1002/cam4.188
34.
ImoukhuedePI, DokunAO, AnnexBH, et al.Endothelial cell-by-cell profiling reveals the temporal dynamics of VEGFR1 and VEGFR2 membrane localization after murine hindlimb ischemia. Am J Physiol Heart Circ Physiol, 2013; 304(8):H1085–H1093; doi: 10.1152/ajpheart.00514.2012
35.
ImoukhuedePI, PopelAS. Expression of VEGF receptors on endothelial cells in mouse skeletal muscle. PLoS One, 2012; 7(9); doi: 10.1371/journal.pone.0044791
36.
ChenS, ImoukhuedePI. Single-cell receptor quantification of an in vitro coculture angiogenesis model reveals VEGFR, NRP1, Tie2, and PDGFR regulation and endothelial heterogeneity. Processes, 2019; 7(6); doi: 10.3390/pr7060356
37.
ChenS, WeddellJC, GuptaP, et al.QFlow cytometry-based receptoromic screening: A high-throughput quantification approach informing biomarker selection and nanosensor development. Methods Mol Biol, 2017; 1570:117–138.
38.
ChenS, GuoX, ImarenezorO, et al.Quantification of VEGFRs, NRP1, and PDGFRs on endothelial cells and fibroblasts reveals serum, intra-family ligand, and cross-family ligand regulation. Cell Mol Bioeng, 2015; 8(3):383–403; doi: 10.1007/s12195-015-0411-x
39.
FangY, MalikM, EnglandSK, et al.Absolute quantification of plasma membrane receptors via quantitative flow cytometry. Methods Mol Biol, 2022; 2475:61–77; doi: 10.1007/978-1-0716-2217-9_4
40.
LanghansSA. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol, 2018; 9(JAN):6; doi: 10.3389/FPHAR.2018.00006/BIBTEX
41.
KanellisJ, PaizisK, CoxAJ, et al.Expression of VEGF receptors on endothelial cells in mouse skeletal muscle. PLoS One, 2015; 1332(5):1696–1706; doi: 10.1371/journal.pone.0044791
42.
EdmondsonR, BroglieJJ, AdcockAF, et al.Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol, 2014; 12(4):207; doi: 10.1089/ADT.2014.573
43.
LinRZ, ChangHY. Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol J, 2008; 3(9–10):1172–1184; doi: 10.1002/BIOT.200700228
44.
ReaK, PinciroliP, SensiM, et al.Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome. Oncotarget, 2015; 6(31):30859–30875; doi: 10.18632/oncotarget.5087
45.
ChenS, LeT, HarleyBAC, et al.Characterizing glioblastoma heterogeneity via single-cell receptor quantification. Front Bioeng Biotechnol, 2018; 6:92; doi: 10.3389/fbioe.2018.00092
46.
SzerlipNJ, PedrazaA, ChakravartyD, et al.Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A, 2012; 109(8):3041–3046; doi: 10.1073/PNAS.1114033109/-/DCSUPPLEMENTAL
47.
ButtiR, DasS, GunasekaranVP, et al.Receptor tyrosine kinases (RTKs) in breast cancer: Signaling, therapeutic implications and challenges. Mol Cancer 2018 17:1, 2018; 17(1):1–18; doi: 10.1186/S12943-018-0797-X
48.
CeciC, AtzoriMG, LacalPM, et al.Role of VEGFs/VEGFR-1 signaling and its inhibition in modulating tumor invasion: Experimental evidence in different metastatic cancer models. Int J Mol Sci, 2020; 21(4); doi: 10.3390/ijms21041388
49.
ChenL, ChengX, TuW, et al.Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells. Cell Oncol, 2019; 42(5):679–690; doi: 10.1007/s13402-019-00455-x
50.
CasalettoJB, McClatcheyAI. Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer, 2012; doi: 10.1038/nrc3277
51.
SherI, AdhamSA, PetrikJ, et al.Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer, 2009; 124(3):553–561; doi: 10.1002/ijc.23963
52.
UmemuraS, SowaY, IizumiY, et al.Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS-mutated ovarian cancer cells with high AXL expression. Cancer Sci, 2020; 111(6):2052–2061; doi: 10.1111/cas.14414
53.
BourgeoisDL, KabarowskiKA, PorubskyVL, et al.High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation. Cancer Cell Int, 2015; 15(1):1–11; doi: 10.1186/S12935-015-0263-4/TABLES/1
54.
HanahanD, WeinbergRA. Hallmarks of cancer: The next generation. Cell, 2011; 144(5):646–674; doi: 10.1016/j.cell.2011.02.013
55.
TeoZL, SavasP, LoiS. Gene expression analysis: Current methods. Mol Pathol Cancer Res, 2017; 107–136; doi: 10.1007/978-1-4939-6643-1_6/TABLES/2
56.
KimH, PhungY, HoM. Changes in global gene expression associated with 3D structure of tumors: An ex vivo matrix-free mesothelioma spheroid model. PLoS One, 2012; 7(6):e39556; doi: 10.1371/JOURNAL.PONE.0039556
57.
NtellasP, MavroeidisL, GkouraS, et al.Old player-new tricks: Non angiogenic effects of the VEGF/VEGFR pathway in cancer. Cancers, 2020; 12(3145):1–28; doi: 10.3390/cancers12113145
58.
BenderRJ, Mac GabhannF. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis. BMC Syst Biol, 2015; 9(1):1–14; doi: 10.1186/s12918-015-0201-z
59.
AminiA, Masoumi MoghaddamS, MorrisDL, et al.Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: From concept to application. J Oncol, 2012; doi: 10.1155/2012/540791
60.
WinerI, WimalasinghamA, BarandaJ, et al.531 A Phase 1b multi-tumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors: Results of the triple-negative breast cancer, ovarian cancer, and endometrial cancer cohorts. J Immunother Cancer, 2021; 9(Suppl 2):A562; doi: 10.1136/JITC-2021-SITC2021.531
61.
ImoukhuedePI, PopelAS. Quantification and cell-to-cell variation of vascular endothelial growth factor receptors. Exp Cell Res, 2011; 317(7):955–965; doi: 10.1016/j.yexcr.2010.12.014
62.
TungJW, HeydariK, TirouvanziamR, et al.Modern flow cytometry: A practical approach. Clin Lab Med, 2007; 27(3):453–468; doi: 10.1016/j.cll.2007.05.001
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
